Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
2.68
+0.02 (0.75%)
Feb 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.66 - 2.77
52 week 1.51 - 5.97
Open 2.69
Vol / Avg. 0.00/487,726.00
Mkt cap 27.62M
P/E     -
Div/yield     -
EPS -0.93
Shares 168.56M
Beta 0.70
Inst. own 0%
Mar 3, 2015
Novogen Ltd Ordinary Shareholders Meeting - 11:30PM EST - Add to calendar
Feb 9, 2015
Novogen Ltd at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -7785.26% -8700.00%
Operating margin -7785.27% -8700.00%
EBITD margin - -6600.00%
Return on average assets -132.92% -145.43%
Return on average equity -279.01% -269.02%
Employees 12 -
CDP Score - -

Address

L 1 16-20 Edgeworth David Ave, Hornsby
SYDNEY, NSW 2077
Australia
+61-2-94724100 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novogen Limited is a drug discovery company. The Company owns two drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs), both small molecule cytotoxics. These technologies target new drug targets with therapeutic potential across the fields of cancer, regenerative medicine, neurodegenerative diseases, musculodegenerative diseases, lysosomal storage diseases, and autoimmune diseases. Novogen has a pipeline of four oncology candidates that are in pre-clinical stage.

Officers and directors

Graham Edmund Kelly Chairman of the Board, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Cristyn Humphreys Chief Operating Officer - Administration and Finance
Bio & Compensation  - Reuters
David Brown Chief Scientific Officer
Bio & Compensation  - Reuters
Andrew Heaton Vice President - Drug Discovery
Bio & Compensation  - Reuters
Lilischkis Kimberley Clinical & Regulatory Affairs Manager
Bio & Compensation  - Reuters
Stephen Palmer Program Director - Degenerative Diseases
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Steven Roy Stent Coffey Non-Executive Director
Bio & Compensation  - Reuters
Peter Gunning Non-Executive Director
Bio & Compensation  - Reuters
John P. O'Connor III Non-Executive Director
Bio & Compensation  - Reuters